摘要
目的 探讨醋酸钙片治疗血液透析患者高磷血症的疗效及有效性.方法 选择2012年1月至2014年1月期间本院进行血液透析治疗的高磷血症患者82例为研究对象,随机分为治疗组41例和对照组41例,治疗组给予醋酸钙治疗,对照组给予碳酸钙治疗.评价两组患者治疗前和治疗8周后的血磷水平、血钙水平、钙磷乘积、血iPTH水平、不良事件及不良反应发生率.结果 治疗后两组患者的血磷水平、钙磷乘积、血iPTH水平低于治疗前,血钙水平高于治疗前,差异有统计学意义（P＜0.05）.治疗组的药物响应比率高于对照组,差异有统计学意义（P＜0.05）.治疗组与对照组比较,不良事件发生率和不良反应发生率的差异无统计学意义（P＞0.05）.结论 醋酸钙治疗血液透析患者高磷血症,能降低患者的钙磷乘积和血iPTH水平,降磷能力较碳酸钙更优。
Objectives To investigate the efficacy and safety of calcium acetate on hyperphosphatemia in patients cured with hemodialysis.Methods 82 hemodialysis patients cured in our hospital with hyperphosphatemia from 2012 January to 2014 January were chosen,and they were randomly divided into the treatment group with 41 cases and the control group with 41 cases.The former is cured with calcium acetate,and the latter cured with calcium carbonate.The blood phosphorus level,blood calcium level,calcium-phosphorus product,blood iPTH level,the incidence of adverse events and the incidence of adverse reactions were compared between the two groups before treatment and 8 weeks after treatment.Results The blood phosphorus level,calcium-phosphorus product,blood iPTH level after treatment decreased？ than before treatment,the blood calcium level increased？ than before treatment in the two groups,the difference was statistically significant（P 〈0.05）.The drug response ratio in treatment group were higher than before treatment,the difference was statistically significant （P 〈 0.05）.Compared the incidence of adverse events and the incidence of adverse reactions in the two groups,the difference was no statistically significant（P 〉0.05）.Conclusions In hemodialysis patients with hyperphosphatemia,calcium acetate can decrease calcium-phosphorus product and blood iPTH level.Calcium cetate is better than calcium carbonate in the ability of reduce blood phosphorus level.
出处
《国际泌尿系统杂志》
2015年第6期874-876,共3页
International Journal of Urology and Nephrology
关键词
肾透析
高磷血症
钙
磷
Renal Dialysis
Hyperphosphatemia
Calcium
Phosphorus
